Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon α plus ribavirin combination therapy

Kanzo/Acta Hepatologica Japonica

Volumn 46, Issue 3, 2005, Pages 107-118

  Toyota, Joji ^c   Karino, Yosiyasu ^c   Akaike, Jun ^c   Ohmura, Takumi ^c   Sato, Takahiro ^c   Yamazaki, Katsu ^c   Kuwata, Yasuaki ^a   Iino, Shiro ^b  

^a Sapporo Kosei General Hospital   (Japan)

^b Kiyokawa Medical Center   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HEMOGLOBIN; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; AGING; ARTICLE; BODY WEIGHT; CHRONIC HEPATITIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 17644389585     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.46.107     Document Type: Article

References (38)

1. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998; 339: 1493-9
2. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998; 339: 1485-2
3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis c virus. Lancet 1998; 352: 1426-2
4. Zeuzeni S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol 2004; 40: 993-9
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a rondomised trial. Lancet 2001; 358: 958-65
6. Glue P, Fang JWS, Rouzier-Panis R, et al. Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556-67
7. Silva M, Poo-Ramire JL, Wanger F, et al. Comparison of Peginterferon-α 2a and Peginterferon-α 2b pharmacokinetics and pharmacodynamics in compare, a randomized, prospective, blinded trial. Hepatology 2004; 40 (suppl. 1): 192 A, abstract 68
8. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon α 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. JID 2004; 189: 964-70
9. Suzuki F, Chayama K, Tsubota A, et al. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 2001; 36: 242-7
10. Layden TJ, Layden JE, Reddy KR, et al. Induction therapy with consensus interferon (CIFN) does not improve sustained virological response in chronic hepatitis C. J of Viral Hepat 2002; 9: 334-9
11. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7
12. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9
13. Reddy KR, Fried MW, Shiffman ML, et al. The influence of cumulative exposure to combination Peginterferon alfa-2a (40 KD) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C. J Hepatology 2004; 40(suppl. 1): 149, abstract 505
14. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52
15. Karino Y, Toyota J, Kuwata Y, et al. Advanced age and serum ribavirin level affect the degree of hemolytic anemia during the combination therapy of IFN-alpha 2b and ribavirin for chronic hepatitis C. Hepatology 2003; 38(suppl. 4): 743 A, abstract 1211
16. Lindahl K, Schvarcz R, Bruchfeld A, et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin induced anaemia. J Viral Hepat 2004; 11: 84-7
17. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infectious Dis 2003; 37: S315-22
18. Sulkowski MS, Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-50
19. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-7
20. Kamar N, Chatelut E, Manolis E, et al. Ribavirin pharmacokinetics in renal and liver transplant patients: Evidence that it depends on renal function. Am J Kidney Dis 2004; 43: 140-6
21. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004
22. Bruno S, Camma C, Di Marco V, et al. Pegintron alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474-81
23. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-82
24. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40: 1450-8
25. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled trial. Gastroenterology 2004; 126: 1302-11
26. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C. a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55
27. Jacobson I, Brown R, McCone J, et al. Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-American(AA) compared to flat dose ribavirin with Peg-interferon alfa-2b combination therapy. Hepatology 2004; 40(suppl. 4): 217A, abstract 125
28. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-induced patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491-9
29. Saeian K, Bajaj JS, Franco J, et al. High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin. Aliment Pharmacol Ther 2004; 20: 1189-93
30. Tsubota A, Hirose Y, Izumi N, et al. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Pharmacol 2003; 55: 360-7
31. Arase Y, Ikeda K, Suzuki F, et al. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004; 39: 1090-4